Major health organizations across the world have changed several definitions of medical terms, including the definitions for “vaccine,” “herd immunity” and “pandemic,” which in turn have a significant impact on everyday life. The U.S. Centers for Disease Control and Prevention is now considering changing the definition of “fully vaccinated”
Israel and Australia have already pushed back the goal post. Citizens must get a booster at six months after their second jab or lose all “passport freedoms.” Australian premier Daniel Andrews has actually stated that, going forward, life for the vaccinated will “be about the maintenance of your vaccination status”
Updating the definition of “fully vaccinated” will also have the side effect of skewing mortality statistics, giving government another round of ammunition for false claims. We’ve been repeatedly told that we’re now in a pandemic of the unvaccinated, and this lie will gain new traction once fully vaccinated people are dropped into the unvaccinated category, six months after their last dose
The National Basketball Association is urging players who got a single-dose Janssen shot as recently as two months ago to get a Pfizer or Moderna booster, or face game-day testing starting December 1, 2021. Players who completed a two-dose regimen are being told to get a booster at the six-month mark
The Occupational Safety and Health Administration (OSHA) is already talking about expanding its COVID-19 vaccine rule, so that small businesses with fewer than 100 employees may also be required to force the jab on their employees or face stiff fines. The public comment period closes December 6, 2021
US National Library of Medicine
National Institutes of Health – 3 Oct 2017
Saghazadeh A – 1, Rezaei N – 2.
Author information
1 Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran; MetaCognition Interest Group (MCIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
2 Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Boston, MA, USA. Electronic address: Rezaei_nima@tums.ac.ir.
Abstract
BACKGROUND:
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder that affects cognitive and higher cognitive functions. Increasing prevalence of ASD and high rates of related comorbidities has caused serious health loss and placed an onerous burden on the supporting families, caregivers, and health care services. Heavy metals are among environmental factors that may contribute to ASD. However, due to inconsistencies across studies, it is still hard to explain the association between ASD and toxic metals. Therefore the objective of this study was to investigate the difference in heavy metal measures between patients with ASD and control subjects.
METHODS:
We included observational studies that measured levels of toxic metals (antimony, arsenic, cadmium, lead, manganese, mercury, nickel, silver, and thallium) in different specimens (whole blood, plasma, serum, red cells, hair and urine) for patients with ASD and for controls. The main electronic medical database (PubMed and Scopus) were searched from inception through October 2016.
RESULTS:
52 studies were eligible to be included in the present systematic review, of which 48 studies were included in the meta-analyses. The hair concentrations of antimony (standardized mean difference (SMD)=0.24; 95% confidence interval (CI): 0.03 to 0.45) and lead (SMD=0.60; 95% confidence interval (CI): 0.17 to 1.03) in ASD patients were significantly higher than those of control subjects. ASD patients had higher erythrocyte levels of lead (SMD=1.55, CI: 0.2 to 2.89) and mercury (SMD=1.56, CI: 0.42 to 2.70). There were significantly higher blood lead levels in ASD patients (SMD=0.43, CI: 0.02 to 0.85). Sensitivity analyses showed that ASD patients in developed but not in developing countries have lower hair concentrations of cadmium (SMD=-0.29, CI: -0.46 to -0.12). Also, such analyses indicated that ASD patients in developing but not in developed lands have higher hair concentrations of lead (SMD=1.58, CI: 0.80 to 2.36) and mercury (SMD=0.77, CI: 0.31 to 1.23). These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with ASD and controls.
CONCLUSION:
The findings help highlighting the role of toxic metals as environmental factors in the etiology of ASD, especially in developing lands. While there are environmental factors other than toxic metals that greatly contribute to the etiology of ASD in developed lands. It would be, thus, expected that classification of ASD includes etiological entities of ASD on the basis of implication of industrial pollutants (developed vs. developing ASD).
Environmental Toxicology and Pharmacology
Volume 38, Issue 3, November 2014, Pages 1016–1024
Highlights
•Autism is a developmental disability characterized by severe, pervasive deficits in social interaction and communications.
•Lead and mercury two of the most common heavy metals in the environment.
•Lead and mercury can lead to autistic disorders.
•Many risk factors contribute to the high level of heavy metals in autistic children.
•Defect in the metabolism of the heavy metals in autistic children also contribute to the high level of these heavy metals in their body.
•Chelating agents can be used in the treatment of the autistic disorders.
Abstract
Aim
Autism is a developmental disability characterized by severe deficits in social interaction and communication. The definite cause of autism is still unknown. The aim of this study is to find out the relation between exposure to Lead and/or mercury as heavy metals and autistic symptoms, dealing with the heavy metals with chelating agents can improve the autististic symptoms.
Method
Blood and hair samples were obtained from 45 children from Upper Egypt with autism between the ages of 2 and 10 years and 45 children served as controls in the same age range, after taken an informed consent and fill a questionnaire to assess the risk factors. The samples were analyzed blindly for lead and mercury by using atomic absorption and ICP-MS. Data from the two groups were compared, then follow up of the autistic children after treatment with chelating agents were done.
Results
The results obtained showed significant difference among the two groups, there was high level of mercury and lead among those kids with autism. Significant decline in the blood level of lead and mercury with the use of DMSA as a chelating agent. In addition, there was decline in the autistic symptoms with the decrease in the lead and mercury level in blood.
Conclusion
Lead and mercury considered as one of the main causes of autism. Environmental exposure as well as defect in heavy metal metabolism is responsible for the high level of heavy metals. Detoxification by chelating agents had great role in improvement of those kids.
US National Library of Medicine
National Institutes of Health – Jan 2005
William M. Pardridge
Department of Medicine, UCLA, Los Angeles, California 90024
Address correspondence and reprint requests to William M. Pardridge, M.D., UCLA Warren Hall, 13-164, 900 Veteran Avenue, Los Angeles,
ABSTRACT
Summary: The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain ∼100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs. Despite the importance of the BBB to the neurotherapeutics mission, the BBB receives insufficient attention in either academic neuroscience or industry programs. The combination of so little effort in developing solutions to the BBB problem, and the minimal BBB transport of the majority of all potential CNS drugs, leads predictably to the present situation in neurotherapeutics, which is that there are few effective treatments for the majority of CNS disorders. This situation can be reversed by an accelerated effort to develop a knowledge base in the fundamental transport properties of the BBB, and the molecular and cellular biology of the brain capillary endothelium. This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences.
VAXXED TV – Nick Johansen #vaxxed #PrayBig
Dr. Judy Mikovits, PhD Research Scientist at #TxMFA #TxMFA2017 Dr. Judy Mikovits, PhD research scientist, dives deep into the crude science of vaccination
Austin Bennett #vaxxed #PrayBig
Dawn Richardson
David Oldham
Barbara Loe Fisher #vaxxed #truth #science #praybig
Q&A vaccine syndrome
Global Vaccine Initiative Houston Protest #TxMFA #TxMFA2017
Jonathan Tommey and The Vaxxed Team hit the ground running at the Texas Medical Freedom Alliance world symposium in Housant, Texas.
They discusses vaccine safety concerns with our #TexasPeeps protesting on the ground and also interview medical doctor, Jim Meehan, M.D. with regard to his passion for exposing the deception endemic to the present vaccine paradigm.
Glaxo’s Vaccine Trials survivor speaks out
David tells his story and presents documentation of his history going through the Glaxo’s trials. His mother was told he had passed as an infant here they kept him as an orphan until 4 years old.
Interview recorded on May 5th, 2017 in The United Kingdom
1 Corinthians 15 Authorized (King James) Version (AKJV)
1 Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand;
2 by which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain.
3 For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures;
4 and that he was buried, and that he rose again the third day according to the scriptures:
Hebrews 6 Authorized (King James) Version (AKJV)
1 Therefore leaving the principles of the doctrine of Christ, let us go on unto perfection; not laying again the foundation of repentance from dead works, and of faith toward God,
2 of the doctrine of baptisms, and of laying on of hands, and of resurrection of the dead, and of eternal judgment.
3 And this will we do, if God permit.
4 For it is impossible for those who were once enlightened, and have tasted of the heavenly gift, and were made partakers of the Holy Ghost,
5 and have tasted the good word of God, and the powers of the world to come,
6 if they shall fall away, to renew them again unto repentance; seeing they crucify to themselves the Son of God afresh, and put him to an open shame.
7 For the earth which drinketh in the rain that cometh oft upon it, and bringeth forth herbs meet for them by whom it is dressed, receiveth blessing from God:
8 but that which beareth thorns and briers is rejected, and is nigh unto cursing; whose end is to be burned.
Educate before you vaccinate!!! tiny.cc/FreeVaccinationEducation
More information on glyphosate in vaccines: ecowatch.com/glyphosate-vaccines-1999343362.html Jeffrey M. Smith is the director of the Institute for Responsible Technology and is one of the world’s leading advocates against GM foods. His book Seeds of Deception is rated the number one book on the subject and has had a substantial influence on public perception and even legislation. Smith has reached tens of millions of people through hundreds of media interviews. He produced the video Hidden Dangers in Kids’ Meals, and also writes a popular monthly syndicated column. He is on the Genetic Engineering Committee of the Sierra Club, was the former vice president of marketing for a GMO detection laboratory, and ran for U.S. Congress in his home state of Iowa to raise public awareness of the health and environmental dangers of GM foods.
Find his books here: amazon.com/Jeffrey-M.-Smith/e/B001JRXVHC/ref=ntt_dp_epwbk_0
Networking, exemption information and doctor resources: tinyurl.com/RevolutionForVaccineChoice
Follow us: facebook.com/RevolutionForChoice
Read all vaccine inserts: tinyurl.com/ReadTheVaccineInsert #RevolutionForChoice #InformedConsent #Monsanto #Pesticides #Glyphosate #EducateBeforeYouVaccinate #VAXXED
“…what we’re told to do.” Full Interview:
Editor: Robin Aris
Air Pollution Linked To Measles Incidence, Proving Immune Status Is Vital In Disease Risk
Posted on: Sunday, May 14th 2017 at 5:45 am
Written By: Sayer Ji, Founder
The idea that measles virus is solely responsible for causing measles infection, and that vaccination alone is the way to prevent it, has been undermined by a new Chinese air pollution study.
A new study published in the journal Environmental Research reveals that exposure to air pollution is significantly associated with measles incidence in China. This is consistent with the view that infection is not solely determined by exposure to a virus particle but also involves the immune status of the subject which depends on various nutritional and environmental factors, including the immunosuppressive function of air pollution. In other words, it’s not just the “germ” alone but the terrain that determines disease.
In the new study titled, “Is short-term exposure to ambient fine particles associated with measles incidence in China? A multi-city study,” Chinese researchers examined the relationship between short-term exposure to ambient particles with a diameter of less than ≤2.5µm (i.e. 2.5 microns thick) and measles incidence in China. They noted that rapid economic development has resulted in “severe particulate matter (PM) air pollution.”
Their method was to collect data on the daily number of new measles cases and concentrations of ambient particles (≤2.5µm) from 21 cities in China between October 2013 and December 2014 and to analyze data to ascertain the effects at the national scale.
Study – Is short-term exposure to ambient fine particles associated with measles incidence in China? A multi-city study.
RESULTS:
A 10µg/m3 increase in PM2.5 at lag 1day, lag 2day and lag 3day was significantly associated with increased measles incidence [relative risk (RR) and 95% confidence interval (CI) were 1.010 (1.003, 1.018), 1.010 (1.003, 1.016) and 1.006 (1.000, 1.012), respectively]. The cumulative relative risk of measles associated with PM2.5 at lag 1-3 days was 1.029 (95% CI: 1.010, 1.048). Stratified analyses by meteorological factors showed that the PM2.5 and measles associations were stronger on days with high temperature, low humidity, and high wind speed.
CONCLUSIONS:
We provide new evidence that measles incidence is associated with exposure to ambient PM2.5 in China. Effective policies to reduce air pollution may also reduce measles incidence.
Nursing Student Dismissed for Refusal to Lie about Vaccines Wins Early Court Victory
By Paul Webber – June 5, 2017
“Nurses Need to Obey the Patient’s Directives, Not Threaten or Lie”
Nurse is dismissed from Baker College in Michigan for questioning vaccines
The nurse files suit against Baker College
Baker College attempts to dismiss the case; Judge denies request
Michigan law protects patient rights
Back in 2013, nursing student Nichole Rolfe, claims she was asked by her Baker college instructors to threaten patients who opted to not vaccinate. The threats included ‘giving them false information’ and even ‘withholding state medical assistance’ to those who questioned whether or not they’d vaccinated. Last week, a judge declined Baker college’s request to dismiss the suit and prevents any severe alterations to the suit. According to olcplc.com, Michigan patients most certainly do have the right to choose (and without intimidation).
Study – Vaccines for measles, mumps and rubella in children
MAIN RESULTS:
We included five randomised controlled trials (RCTs), one controlled clinical trial (CCT), 27 cohort studies, 17 case-control studies, five time-series trials, one case cross-over trial, two ecological studies, six self controlled case series studies involving in all about 14,700,000 children and assessing effectiveness and safety of MMR vaccine. Based on the available evidence, one MMR vaccine dose is at least 95% effective in preventing clinical measles and 92% effective in preventing secondary cases among household contacts.Effectiveness of at least one dose of MMR in preventing clinical mumps in children is estimated to be between 69% and 81% for the vaccine prepared with Jeryl Lynn mumps strain and between 70% and 75% for the vaccine containing the Urabe strain. Vaccination with MMR containing the Urabe strain has demonstrated to be 73% effective in preventing secondary mumps cases. Effectiveness of Jeryl Lynn containing MMR in preventing laboratory-confirmed mumps cases in children and adolescents was estimated to be between 64% to 66% for one dose and 83% to 88% for two vaccine doses. We did not identify any studies assessing the effectiveness of MMR in preventing rubella.The highest risk of association with aseptic meningitis was observed within the third week after immunisation with Urabe-containing MMR (risk ratio (RR) 14.28; 95% confidence interval (CI) from 7.93 to 25.71) and within the third (RR 22.5; 95% CI 11.8 to 42.9) or fifth (RR 15.6; 95% CI 10.3 to 24.2) weeks after immunisation with the vaccine prepared with the Leningrad-Zagreb strain. A significant risk of association with febrile seizures and MMR exposure during the two previous weeks (RR 1.10; 95% CI 1.05 to 1.15) was assessed in one large person-time cohort study involving 537,171 children aged between three months and five year of age. Increased risk of febrile seizure has also been observed in children aged between 12 to 23 months (relative incidence (RI) 4.09; 95% CI 3.1 to 5.33) and children aged 12 to 35 months (RI 5.68; 95% CI 2.31 to 13.97) within six to 11 days after exposure to MMR vaccine. An increased risk of thrombocytopenic purpura within six weeks after MMR immunisation in children aged 12 to 23 months was assessed in one case-control study (RR 6.3; 95% CI 1.3 to 30.1) and in one small self controlled case series (incidence rate ratio (IRR) 5.38; 95% CI 2.72 to 10.62). Increased risk of thrombocytopenic purpura within six weeks after MMR exposure was also assessed in one other case-control study involving 2311 children and adolescents between one month and 18 years (odds ratio (OR) 2.4; 95% CI 1.2 to 4.7). Exposure to the MMR vaccine was unlikely to be associated with autism, asthma, leukaemia, hay fever, type 1 diabetes, gait disturbance, Crohn’s disease, demyelinating diseases, bacterial or viral infections.
AUTHORS’ CONCLUSIONS:
The design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-marketing, are largely inadequate. The evidence of adverse events following immunisation with the MMR vaccine cannot be separated from its role in preventing the target diseases.
Fluzone contains:
Formaldehyde: A chemical usually used in building materials, as well as industrial fungicide. In medical laboratories, it is used as a preservative. Long-term effects have not been fully studied, as the National Cancer Institute admits. A study of funeral industry workers found a link between formaldehyde and myeloid lukemia, and professionals such as anatomists and embalmers reported increased risks of leukemia and brain cancer when working with formaldehyde.
Octylphenol ethoxylate (Triton X-100): is a product created by a few chemical companies including DOW. It is used for “wetting, detergency, superior hard surface, metal cleaning and excellent emulsification” in paints, coatings, oilfield chemicals, textiles, and industrial cleaners. In 1995 an article raised a question if this chemical is toxic to the reproductive system. In the fact sheet for Triton, the chemical is listed as possibly toxic to specifically the female reproductive system, and mutagenic for mammalian somatic cells (may change DNA of skin, bones, blood and connective tissue cells.
Thimerosal (standard dosage multi-dose vial): is a mercury-based preservative used in flu shots and some childhood vaccines. The ingredient has caused a lot of controversy since 1990s. It is a neurotoxin; it can cause nerve damage, and FDA knows of numerous cases of mercury poisoning caused by thimerosal.
Other ingredients in Fluzone are: sodium phosphate-buffered isotonic sodium chloride solution and gelatin
Read more about Fluzone reactions here : More Than 100 Seniors Died After Receiving This Flu Shot Given By Pharmacies
by Yelena Sukhoterina | January 6, 2016
As it happens every winter, the marketing push for receiving a flu shot continues. CVS is offering a 20% shopping pass when you get your flu shot. They are also marketing a high-dose vaccine, which is of course more profitable for the manufacturer and the pharmacy, but there are plenty of reasons to be wary of it — especially for seniors.
Fluzone® High-Dose is an injectable vaccine, specifically approved for people ages 65 and older. Manufactured by Sanofi Pasteur, this shot contains three flu strains and four times more antigen (substance that causes an immune response) than regular flu shots, claims CVS Pharmacy (Rite Aid also offers it and admits that “more studies are being done” to see whether it actually offers an improvement at all).
The pharmacy does admit that the vaccine is not recommended for anyone who has experienced an adverse reaction (especially Guillain-Barré syndrome) to vaccines in the past.
But between their marketing campaigns and promoting a 20% shopping coupon, they omitted a vital piece of information: 105 seniors died after taking part in two Fluzone high-dose vaccine trials, and 91 died after getting the regular Fluzone vaccine.
Vaccines contain many toxic ingredients, but they vary by manufacturer.
Other flu shots are made from different potentially toxic ingredients:
Afluria (Trivalent) contains:
Monobasic sodium phosphate (MSP): when used in high doses during colon cleansing, it has caused acute phosphate nephropathy, and permanent impairment of renal functions. It has also caused seizures, and cardiac arrhythmias.
Dibasic sodium phosphate and monobasic potassium phosphate: Phosphates are often used in food as preservatives, acidifying, and emulsifying agents. German researchers concluded that it is “damaging to health,” especially to the renal function, and is linked to cardiovascular and overall mortality.
Potassium chloride: has been most commonly linked to digestive problems and vomiting, but in severe cases it can lead to severe allergic reactions, chest pains, irregular heartbeat, confusion, and paralysis.
Calcium chloride: may lead to cardiovascular issues.
Sodium taurodeoxycholate: have been associated to promote tumor growth, particularly in pancreas, colon, and throat, studies show.
Neomycin sulfate: in rare cases has been linked to drowsiness, loss of hearing, difficulty breathing, rash, and weakness.
Polymyxin B: is an antibiotic, whose side effects include neurotoxic and nephrotoxic reactions: rising blood levels, dizziness, apnea, fever, and headache.
Mercury: a heavy metal responsible for poisoning, and damage to many organs leading to severe illnesses, including severe insomnia, and neurological disorders.
Beta-propiolactone is a carcinogen and a possible toxin to liver, skin, respiratory tract, and gastrointestinal tract.
Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer’s Disease
Abstract
In this paper, I have summarized the experimental and largely clinical evidence that implicates aluminum as a primary etiological factor in Alzheimer’s disease. The unequivocal neurotoxicity of aluminum must mean that when brain burdens of aluminum exceed toxic thresholds that it is inevitable that aluminum contributes toward disease. Aluminum acts as a catalyst for an earlier onset of Alzheimer’s disease in individuals with or without concomitant predispositions, genetic or otherwise. Alzheimer’s disease is not an inevitable consequence of aging in the absence of a brain burden of aluminum.
EVIDENCE NOW POINTS TO ALUMINUM AS A CONTRIBUTORY FACTOR IN ALL FORMS OF ALZHEIMER’S DISEASE
Aluminum is unquestionably neurotoxic [1] and it is accepted as the cause of encephalopathies in, for example, individuals undergoing renal dialysis [2] and similarly in individuals who have received aluminum-based prostheses [3]. There are myriad ways by which aluminum can exert toxicity; its Al3 + (aq) ion is highly biologically reactive, but to do so and thereby bring about change in a biochemical system, the aluminum content of any compartment, such as a tissue, must achieve a toxic threshold or burden [4]. However, aluminum-induced encephalopathies are not Alzheimer’s disease, though they may share some similar neuropathological hallmarks [5]; they are acute conditions whereas Alzheimer’s disease might now be considered as an acute response to chronic intoxication byaluminum [1].
Shocker: study unwittingly links vaccines to autism
Jun 14 2017
by Jon Rappoport
A new study links fever in pregnant women to an increased risk of autism in their babies.
MedicalNewsToday (6/13/17): “A study of a large group of children found a link between raised risk of autism spectrum disorder and their mothers reporting fever during pregnancy. The link was strongest with fevers reported during the second trimester.”
“The study – led by the Mailman School of Public Health at Columbia University in New York City, NY – also found that the risk of autism increased in line with the number of fevers reported after 12 weeks of gestation – rising to 300 percent higher risk [of autism] with reports of three or more fevers.”
Next, here is a one-word item from the World Health Organization web page, Vaccine Safety Basics. The item comes under the heading of “minor vaccine reactions,” and applies to every vaccine: the reaction is FEVER.
Pregnant woman gets vaccines. Vaccines cause fevers. Fevers are linked to autistic babies.
Here is a CDC list of vaccines given to pregnant women, under various conditions: HepA, HepB, Flu, Tdap (tetanus, diphtheria, pertussis), meningococcal, polio, Rabies. Fever, as a typical and minor adverse effect, would be expected and ignored for ANY AND ALL of these vaccines.
Accepting the finding of the new study, cited above—routine vaccination for pregnant women is linked to an increased risk of autism in their babies.
That’s it in a nutshell.
Fever in pregnancy tied to higher risk of autism
By Catharine Paddock PhD
published Tuesday 13 June 2017
The risk of developing autism spectrum disorder is stronger among children whose mothers experienced fever during pregnancy.
A study of a large group of children found a link between raised risk of autism spectrum disorder and their mothers reporting fever during pregnancy. The link was strongest with fevers reported during the second trimester.
The study – led by the Mailman School of Public Health at Columbia University in New York City, NY – also found that the risk of autism increased in line with the number of fevers reported after 12 weeks of gestation – rising to 300 percent higher risk with reports of three or more fevers.
In the journal Molecular Psychiatry, the researchers say that their findings support the idea that infection in pregnancy – and the way in which the immune system responds to it – may play a role in the development of some cases of autism.
Prenatal fever and autism risk
Abstract
Some studies suggest that prenatal infection increases risk of autism spectrum disorders (ASDs). This study was undertaken in a prospective cohort in Norway to examine whether we could find evidence to support an association of the prenatal occurrence of fever, a common manifestation of infection, with ASD risk. Prospective questionnaires provided maternal exposure data; case status was established from clinical assessments and registry linkages. In a large, prospectively ascertained cohort of pregnant mothers and their offspring, we examined infants born greater than or equal to32 weeks for associations between fever exposure in each trimester and ASD risk using logistic regression. Maternal exposure to second-trimester fever was associated with increased ASD risk, adjusting for presence of fever in other trimesters and confounders (adjusted odds ratio (aOR), 1.40; 95% confidence interval, 1.09–1.79), with a similar, but nonsignificant, point estimate in the first trimester. Risk increased markedly with exposure to three or more fever episodes after 12 weeks’ gestation (aOR, 3.12; 1.28–7.63). ASD risk appears to increase with maternal fever, particularly in the second trimester. Risk magnified dose dependently with exposure to multiple fevers after 12 weeks’ gestation. Our findings support a role for gestational maternal infection and innate immune responses to infection in the pathogenesis of at least some cases of ASD.
Vaccine injury testimony
Monsanto Admits Injecting Glyphosate a Hazard – Too Bad It’s In Vaccines
Tue 9:30 am UTC, 13 Jun 2017
posted by Gordon
Monsanto Toxicologist Donna Farmer recently made the following statement regarding the toxicity of Glyphosate:
“I’ll give you an example of one of the studies,” she said during the debate, which was aired as part of The Doctors, an award-winning TV show. “They actually injected the Round-Up formulation into the abdomen of the animals and they did have an effect. But that’s not a relevant route of exposure for somebody who is going to be spraying that herbicide. So that’s what we look at and the regulatory agencies look at and, like the other bodies at the World Health Organization. IARC only looks and says, “If I inject it there’s a hazard.” So there’s different ways we look at the data.”
Interestingly enough, Glyphosate is a known vaccine contaminant in vaccines deemed “acceptable” by the FDA.
This list of vaccine ingredients indicates the culture media used in the production of common vaccines and the excipients they contain. Most vaccines listed are produced on cultures containing either egg, which are allowed to contain 0.05 mg/Kg glyphosate residues, or Bovine serum albumin, which are from cows allowed to eat fodder that contain 500 mg/Kg glyphosate residues. Also listed are substances used in the manufacturing process.
Study – Relevance of Neuroinflammation and Encephalitis in Autism
Published online 2016 Jan 19
Abstract
In recent years, many studies indicate that children with an autism spectrum disorder (ASD) diagnosis have brain pathology suggestive of ongoing neuroinflammation or encephalitis in different regions of their brains. Evidence of neuroinflammation or encephalitis in ASD includes: microglial and astrocytic activation, a unique and elevated proinflammatory profile of cytokines, and aberrant expression of nuclear factor kappa-light-chain-enhancer of activated B cells. A conservative estimate based on the research suggests that at least 69% of individuals with an ASD diagnosis have microglial activation or neuroinflammation. Encephalitis, which is defined as inflammation of the brain, is medical diagnosis code G04.90 in the International Classification of Disease, 10th revision; however, children with an ASD diagnosis are not generally assessed for a possible medical diagnosis of encephalitis. This is unfortunate because if a child with ASD has neuroinflammation, then treating the underlying brain inflammation could lead to improved outcomes. The purpose of this review of the literature is to examine the evidence of neuroinflammation/encephalitis in those with an ASD diagnosis and to address how a medical diagnosis of encephalitis, when appropriate, could benefit these children by driving more immediate and targeted treatments.
Flu shots with side-effects on offer again
Natasha Bita, Consumer Editor
TheAustralian – 12:00AM February 16, 2012
Perth mother Kirsten Button, whose toddler Saba suffered brain damage after her Fluvax shot in 2010, said yesterday she was “shocked” the government would award the contract to CSL when it did not know why Fluvax had caused so many febrile convulsions. “What assurance does the public have, when they have not explained to us what happened with Fluvax in the first place?” Ms Button said.
She said Saba had been in perfect health before her flu shot, but 16 hours later was on life support, with brain injury and organ damage.
Now two months shy of her third birthday, Saba has epilepsy and is fed through a tube.
“She doesn’t talk, she doesn’t walk, she doesn’t eat and she can’t see properly,” Ms Button said. However, the little girl does occasionally reward her parents with a smile.
CSL was awarded the $117m contract in December, and the information was published on the federal government’s tender database last Friday.
Sanofi-Aventis was awarded a $69.5m contract while GlaxoSmithKline received a $14.7m contract – both to supply seasonal and pandemic flu vaccines for five years.
The contracts coincide with a new TGA review that reveals the risk of side-effects in adults from Fluvax in 2010 was “modestly higher” than for two rival brands.
Fluvax was 14.5 times more likely to cause a headache and nine times more likely to cause fatigue than Vaxigrip.
The data – based on an analysis of “adverse events” in adults vaccinated during the 2010 flu season – reveals Fluvax was 4.4 times more likely to cause vomiting and 10.7 times more likely to cause injection site pain than Influvac, made in The Netherlands for Abbott Australasia.
Lessons learnt in Japan from adverse reactions to the HPV vaccine: a medical ethics perspective
Abstract
The human papillomavirus (HPV) vaccine has been linked to a number of serious adverse reactions. The range of symptoms is diverse and they develop in a multi-layered manner over an extended period of time. The argument for the safety and effectiveness of the HPV vaccine overlooks the following flaws: (i) no consideration is given to the genetic basis of autoimmune diseases, and arguments that do not take this into account cannot assure the safety of the vaccine; (ii) the immune evasion mechanisms of HPV, which require the HPV vaccine to maintain an extraordinarily high antibody level for a long period of time for it to be effective, are disregarded; and (iii) the limitations of effectiveness of the vaccine. We also discuss various issues that came up in the course of developing, promoting and distributing the vaccine, as well as the pitfalls encountered in monitoring adverse events and epidemiological verification.
VaxXed Stories: Jena in Seattle
Jena shares the story of her two boys vaccine injuries with the VaxXed team in Seattle, Washington. Camera and editing by Joshua Coleman
Study – Autism Occurrence by MMR Vaccine Status Among US Children With Older Siblings With and Without Autism
April 21, 2015
Abstract
Importance Despite research showing no link between the measles-mumps-rubella (MMR) vaccine and autism spectrum disorders (ASD), beliefs that the vaccine causes autism persist, leading to lower vaccination levels. Parents who already have a child with ASD may be especially wary of vaccinations.
Objective To report ASD occurrence by MMR vaccine status in a large sample of US children who have older siblings with and without ASD.
Design, Setting, and Participants A retrospective cohort study using an administrative claims database associated with a large commercial health plan. Participants included children continuously enrolled in the health plan from birth to at least 5 years of age during 2001-2012 who also had an older sibling continuously enrolled for at least 6 months between 1997 and 2012.
Exposures MMR vaccine receipt (0, 1, 2 doses) after 1 year of age.
Main Outcomes and Measures ASD status defined as 2 claims with a diagnosis code in any position for autistic disorder or other specified pervasive developmental disorder (PDD) including Asperger syndrome, or unspecified PDD (International Classification of Diseases, Ninth Revision, Clinical Modification 299.0x, 299.8x, 299.9x).
Results Of 95 727 children with older siblings, 994 (1.04%) were diagnosed with ASD and 1929 (2.02%) had an older sibling with ASD. Of those with older siblings with ASD, 134 (6.9%) had ASD, vs 860 (0.9%) children with unaffected siblings (P < .001). MMR vaccination rates (≥1 dose) were 84% (n = 78 549) at age 2 years and 92% (n = 86 063) at age 5 years for children with unaffected older siblings, vs 73% (n = 1409) at age 2 years and 86% (n = 1660) at age 5 years for children with affected siblings. MMR vaccine receipt was not associated with an increased risk of ASD at any age. For children with older siblings with ASD, at age 2, the adjusted relative risk (RR) of ASD for 1 dose of MMR vaccine vs no vaccine was 0.76 (95% CI, 0.48-1.22; P = .25), and at age 5, the RR of ASD for 2 doses compared with no vaccine was 0.56 (95% CI, 0.30-1.04; P = .07). For children whose older siblings did not have ASD, at age 2, the adjusted RR of ASD for 1 dose was 0.91 (95% CI, 0.68-1.20; P = .50) and at age 5, the RR of ASD for 2 doses was 1.09 (95% CI, 0.76-1.54; P = .65).
Conclusions and Relevance In this large sample of privately insured children with older siblings, receipt of the MMR vaccine was not associated with increased risk of ASD, regardless of whether older siblings had ASD. These findings indicate no harmful association between MMR vaccine receipt and ASD even among children already at higher risk for ASD.
Says 1 in 45 Children Now Have Autism. Don’t Worry, Nothing To See Here
Published December 8, 2015
A total of 2.24% of U.S. children (1 in 45 children) aged 3 to 17 years have autism spectrum disorder (ASD), according to new statistics released by the 2014 National Health Interview Survey. The new figure is up from 1.25% reported from 2011 to 2013. The prevalence of developmental delay fell to 3.57% from 4.84%, while the rate of intellectual disability remained virtually unchanged at 1.1%.1
The Centers for Disease Control and Prevention (CDC) attributes the significant jump in autism rates on the new format of the survey, which asked parents about autism before asking them if their child had an “other developmental delay.”1 In other words, the change in the order of the questions in the survey may have influenced parents to more likely report autism.
Regardless of the revised question ordering, the rates of autism have continued to increase dramatically during the past three decades:
1980’s: Two studies (1987 & 1989) found 1 in 2500-3000 U.S. children had autism2 3
2000: American Academy of Neurology and Child Neurology Society estimate 1 in 500 US children had autism. 2003-2004: Study (2006) revealed 1 in 188 U.S. children had autism5
2007: CDC states 1 in 150 U.S. children had autism6
2009: CDC states 1 in 110 U.S. children had autism7
2012: CDC states 1 in 88 U.S. children had autism8
2014: CDC states 1 in 68 U.S. children aged eight had autism9
Even though in 2014, the CDC “officially” admitted that 1 in 68 US children eight years old were found to have autism, in 2013 a CDC national health survey found that 1 in 50 children between the ages of 6 and 17 were diagnosed with ASD in 2011-2012.10 The authors of that 2013 federal health survey stated that:
The reported prevalence of ASD has increased in recent decades. For example, data from the Centers for Disease Control and Prevention’s (CDC) National Health Interview Survey (NHIS) revealed a nearly fourfold increase in parent-reported ASD between the 1997–1999 and 2006–2008 surveillance periods, and CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network revealed a 78% increase in ASD prevalence between 2002 and 2008.
MARC J. BERN & PARTNERS LLP Files Lawsuits For A Hundred Individuals Against Merck Alleging Shingles/Zostavax Vaccine Is Defective*
MARC J. BERN & PARTNERS LLP, the attorneys who last month filed their first complaint in Philadelphia Court of Common Pleas on behalf of Jorja Bently, today have filed complaints for another 100 plaintiffs against Merck regarding its Shingles vaccine, Zostavax. The assertions are wide ranging and include plaintiffs claiming to have suffered various side effects which include contracting shingles, chickenpox, high blood pressure, intense neuropathic pain, eye injuries, headaches, dizziness amongst others.
It is alleged by Marc J. Bern & Partners LLP that “Merck knew and had reason to know that its Zostavax vaccine was inherently defective and unreasonably dangerous as designed” that “Merck downplayed the serious and dangerous side effects of its product to encourage sales of the product; consequently, Merck placed its profits above its customers’ safety.” According to founding Partner Marc J Bern, the firm is currently representing nearly 5000 claimants and has thousands more filings to follow. “We have been investigating this drug for quite some time. We steadfastly believe in the merits of this litigation. This vaccination is at best 50 percent effective. Either it is not effective or it causes shingles or a host of other side effects. What is most troubling is that Merck had a better alternative on hand when this product was released.” says Bern.
Thousands Sue Merck for Shingles Vaccine “Causing What It’s Supposed to Prevent”
By Annabelle Bamforth – April 22, 2017
Merck has explicitly stated that those who receive the Zostavax vaccine “may still get shingles.” However, Bouk argued that some people may be contracting shingles as a side effect of the vaccine itself due to the live virus strain in the vaccine, not because people are experiencing shingles despite the vaccine.
Bouk went on to say that “there is a study out there that shows that in 50% of the patients that actually get the vaccine, that sometimes they don’t get shingles — the virus goes straight to manifesting in the central nervous system. It’s possible that you could get the vaccine and get meningitis or encephalitis without ever actually exhibiting shingles.” Bouk advises that patients weigh the risks of Zostavax before receiving the vaccine.
While GSK seeks approval of Shingrix, which could lead to their product edging out Zostavax, a large number of claims have been filed against Merck. The Mark J. Bern Partners law firm “is currently representing nearly 5000 claimants and has thousands more filings to follow.”
Shingles Vaccine Zostavax Is Causing What It’s Designed To Prevent
April 19, 2017
By now I think most people have seen the commercials on television telling us that if we’ve ever had the chicken pox at any point in our lives, then the shingles virus is already inside of us. As it stands right now, there is a vaccine for shingles called Zostavax, but what we’re finding out now about this vaccine makes it seem like it might be pretty dangerous or at least cause some side effects that are actually the same as what we’d see from shingles. Ring of Fire’s Farron Cousins talks with Attorney Troy Bouk about the dangers associated with Zostavax.
London UK vaccine injuries #vaxxed #praybig #truth #science
INTERNATIONAL HUMANITARIAN LAW STATES – IT IS ILLEGAL TO TAKE AWAY ANYONES RIGHT OF INFORMED CONSENT! THAT LAW STILL STANDS!
Informed Consent!
The Supreme Court has spoken: even a “…diminished expectation of privacy does not diminish [your] privacy interest in preventing a government agent from piercing [your] skin…. this Court has never retreated from its recognition that any compelled intrusion into the human body implicates significant, constitutionally protected privacy interests…” (Missouri v McNeely, 2013
members of the public have the right to make informed consent decisions, even if a decision may be considered a “bad” decision by the Government. The Supreme Court indicated, in Thompson v Western States 2016 Significantly, there is also the UN Declaration on BioEthics, negotiated in Geneva, using language similar to the Nuremberg Code and clearly applies to both treatment and experiment:
Article 6 – “Consent – 1. Any preventive, diagnostic and therapeutic medical intervention is only to be carried out with the prior, free and informed consent of the person concerned, based on adequate information. The consent should, where appropriate, be express and may be withdrawn by the person concerned at any time and for any reason without disadvantage or prejudice. 2. Scientific research should only be carried out with the prior, free, express and informed consent of the person concerned. The information should be adequate, provided in a comprehensible form and should include modalities for withdrawal of consent. Consent may be withdrawn by the person concerned at any time and for any reason without any disadvantage or prejudice.
You Can Say NO, To Forced Vaccination And Suffer No Penalty. But, You Have To make A Statement In A Legal Way, In A Specific Way,
Vitamin D supplementation improves autism in children, according to new study
Furthermore, children who received vitamin D supplementation experienced increased cognitive awareness, social awareness and social cognition compared to those who only received the placebo. Vitamin D supplementation significantly decreased repetitive hand movements, random noises, jumping and restricted interests.
The researchers concluded,
“This study is the first double-blinded RCT proving the efficacy of vitamin D3 in ASD patients…Oral vitamin D supplementation may safely improve signs and symptoms of ASD and could be recommended for children with ASD.”
The study also mentioned that the supplementation regimen was well tolerated among the children. Only five children experienced minor side effects during the four-month study period, such as skin rashes, itching and diarrhea.
Study – Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder.
RESULTS:
Supplementation of vitamin D was well tolerated by the ASD children. The daily doses used in the therapy group was 300 IU vitamin D3/kg/day, not to exceed 5,000 IU/day. The autism symptoms of the children improved significantly, following 4-month vitamin D3 supplementation, but not in the placebo group. This study demonstrates the efficacy and tolerability of high doses of vitamin D3 in children with ASD.
CONCLUSIONS:
This study is the first double-blinded RCT proving the efficacy of vitamin D3 in ASD patients. Depending on the parameters measured in the study, oral vitamin D supplementation may safely improve signs and symptoms of ASD and could be recommended for children with ASD. At this stage, this study is a single RCT with a small number of patients, and a great deal of additional wide-scale studies are needed to critically validate the efficacy of vitamin D in ASD.
Study – Vitamin D and omega-3 fatty acid supplements in children with autism spectrum disorder: a study protocol for a factorial randomised, double-blind, placebo-controlled trial
METHODS/DESIGN:
Children with ASD living in New Zealand (n = 168 children) will be randomised to one of four treatments daily: vitamin D (2000 IU), n-3 LCPUFAs (722 mg DHA), vitamin D (2000 IU) + n-3 LCPUFAs (722 mg DHA) or placebo for 12 months. All researchers, participants and their caregivers will be blinded until the data analysis is completed, and randomisation of the active/placebo capsules and allocation will be fully concealed from all mentioned parties. The primary outcome measures are the change in social-communicative functioning, sensory processing issues and problem behaviours between baseline and 12 months. A secondary outcome measure is the effect on gastrointestinal symptoms. Baseline data will be used to assess and correct basic nutritional deficiencies prior to treatment allocation. For safety measures, serum 25-hydroxyvitamin D 25(OH)D and calcium will be monitored at baseline, 6 and 12 months, and weekly compliance and gastrointestinal symptom diaries will be completed by caregivers throughout the study period.
DISCUSSION:
To our knowledge there are no randomised controlled trials assessing the effects of both vitamin D and DHA supplementation on core symptoms of ASD. If it is shown that either vitamin D, DHA or both are effective, the trial would reveal a non-invasive approach to managing ASD symptoms.
Study – Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children
RESULTS:
Fifty-seven percent of the patients in the present study had vitamin D deficiency, and 30% had vitamin D insufficiency. The mean 25-OHD levels in patients with severe autism were significantly lower than those in patients with mild/moderate autism. Serum 25-OHD levels had significant negative correlations with Childhood Autism Rating Scale (CARS) scores. Of the ASD group, 106 patients with low-serum 25-OHD levels (<30 ng/ml) participated in the open label trial. They received vitamin D3 (300 IU/kg/day not to exceed 5000 IU/day) for 3 months. Eighty-three subjects completed 3 months of daily vitamin D treatment. Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
CONCLUSION:
Vitamin D is inexpensive, readily available and safe. It may have beneficial effects in ASD subjects, especially when the final serum level is more than 40 ng/ml.
Study – Clinical improvement following vitamin D3 supplementation in Autism Spectrum Disorder
Abstract
Objective High prevalence of vitamin D deficiency was previously reported in children with Autism Spectrum Disorder (ASD), but little is known about the efficacy of vitamin D3 treatment in ASD, although data from pilot studies seem promising. We hypothesized that serum vitamin D levels are reduced in ASD and correlate with the severity of disease. Also, we hypothesized that vitamin D3 treatment may be beneficial for a considerable portion of children with ASD. Methods In total, 215 children with ASD and 285 healthy control children were recruited in our study. Thirty seven of 215 ASD children received vitamin D3 treatment. The Autism Behaviour Checklist (ABC) and the Childhood Autism Rating Scale (CARS) were used to assess autism symptoms. High-performance liquid chromatography was used to assess the serum 25-hydroxyvitamin D [25(OH) D] level. Evaluations of ABC, CARS, and serum 25(OH) D levels were performed before and after 3 months of treatment. Results Serum levels of 25(OH) D were significantly lower in ASD children than typically developing children. Levels of serum 25(OH) D were negatively correlated with ABC total scores and language subscale scores. After vitamin D3 supplementation, symptom scores were significantly reduced on the CARS and ABC. In addition, the data also suggest that treatment effects were more pronounced in younger children with ASD. Conclusion Vitamin D deficiency might contribute to the aetiology of ASD. Supplementation of vitamin D3, which is a safe and cost-effective form of treatment, may significantly improve the outcome of some children with ASD, especially younger children (identifier ChiCTR-CCC-13004498). Clinical Trial Registration The trial ‘Association of Polymorphisms of Vitamin D Metabolism-Related Genes With Autism and the Treatment of Autism with Vitamin D’ has been registered at www.chictr.org/cn/proj/show.aspx ? proj=6135 (identifier ChiCTR-CCC-13004498).
the news network 